Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Conditions
IgAN · C3G · Complement-mediated Kidney Disease · IgA Nephropathy (IgAN) · IC-MPGN
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
ADARx Clinical Site, Doral, Florida, United States
ADARx Clinical Site, Miami, Florida, United States
ADARx Clinical Site, Pembroke Pines, Florida, United States
ADARx Clinical Site, Iowa City, Iowa, United States
ADARx Clinical Site, Shreveport, Louisiana, United States
ADARx Clinical Site, Shelby, Michigan, United States
ADARx Clinical Site, Great Neck, New York, United States
ADARx Clinical Site, Columbus, Ohio, United States
ADARx Clinical Site, Dakota Dunes, South Dakota, United States
ADARx Clinical Site, Dallas, Texas, United States
ADARx Clinical Site, Houston, Texas, United States
ADARx Clinical Site, Liverpool, New South Wales, Australia
ADARx Clinical Site, Wollongong, New South Wales, Australia
ADARx Clinical Site, Sydney, Australia
ADARx Clinical Site, Woolloongabba, Australia
ADARx Clinical Site, Hong Kong, Hong Kong
ADARx Clinical Site, Shatin, Hong Kong
ADARx Clinical Site, Wŏnju, Gangwon-do, South Korea
ADARx Clinical Site, Cheonan, South Korea
ADARx Clinical Site, Daegu, South Korea
ADARx Clinical Site, Gyeonggi-do, South Korea
ADARx Clinical Site, Seoul, South Korea
ADARx Clinical Site, Seoul, South Korea
ADARx Clinical Site, Seoul, South Korea
ADARx Clinical Site, Seoul, South Korea
ADARx Clinical Site, Barcelona, Spain
ADARx Clinical Site, Madrid, Spain
ADARx Clinical Site, Seville, Spain
ADARx Clinical Site, Newcastle upon Tyne, United Kingdom
Study leads
Aditya Patel, MD
Study Director
ADARx Pharmaceuticals, Inc.